Get the Stockscreener App
0.333
4.86%
-0.017
Pre-market:
.33
-0.003
-0.90%
Heron Therapeutics Inc stock is traded at $0.333, with a volume of 1.79M.
It is down -4.86% in the last 24 hours and down -32.15% over the past month.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$0.35
Open:
$0.3427
24h Volume:
1.79M
Relative Volume:
0.60
Market Cap:
$63.22M
Revenue:
$150.71M
Net Income/Loss:
$-30.94M
P/E Ratio:
-1.8846
EPS:
-0.1767
Net Cash Flow:
$-20.86M
1W Performance:
+6.42%
1M Performance:
-32.15%
6M Performance:
-66.58%
1Y Performance:
-74.38%
1-Day Range:
$0.33
$0.3507
1-Week Range:
$0.3106
$0.355
52-Week Range:
$0.2975
$1.575
Heron Therapeutics Inc Stock (HRTX) Company Profile
Name
Heron Therapeutics Inc
Sector
Industry
Phone
(858) 251-4400
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.333 | 66.45M | 150.71M | -30.94M | -20.86M | -0.1767 |
VRTX
Vertex Pharmaceuticals Inc
|
521.12 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.65 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.31 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
135.61 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.68 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-26 | Downgrade | Needham | Buy → Hold |
| Jun-09-25 | Initiated | H.C. Wainwright | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-24 | Initiated | CapitalOne | Overweight |
| Mar-13-24 | Reiterated | Needham | Buy |
| May-27-20 | Initiated | Guggenheim | Buy |
| Feb-20-20 | Reiterated | Needham | Buy |
| Jan-16-19 | Reiterated | Needham | Buy |
| Apr-05-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Mar-01-18 | Reiterated | Needham | Buy |
| Jan-03-18 | Initiated | Leerink Partners | Outperform |
| Sep-27-17 | Initiated | Northland Capital | Outperform |
| Feb-27-17 | Initiated | Needham | Buy |
| Oct-26-16 | Initiated | Aegis Capital | Buy |
| Sep-06-16 | Resumed | Lake Street | Buy |
| May-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Dec-10-15 | Initiated | Lake Street | Buy |
| Sep-23-15 | Reiterated | Leerink Partners | Outperform |
| Sep-02-15 | Initiated | BofA/Merrill | Buy |
| Aug-03-15 | Reiterated | Brean Capital | Buy |
| Jun-30-15 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-19-15 | Reiterated | Leerink Partners | Outperform |
| Aug-07-14 | Initiated | Noble Financial | Buy |
View All
Heron Therapeutics Inc Stock (HRTX) Latest News
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? - Stocktwits
10,550,750 Shares in Heron Therapeutics, Inc. $HRTX Bought by BlackRock Inc. - MarketBeat
Heron Therapeutics stock trades at penny level as biotech focuses on pain and oncology pipeline - ad-hoc-news.de
AXD2 Forecast — Price Target — Prediction for 2027 - tradingview.com
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Heron Therapeutics Stock Short Interest Rises to 31.36% - Quiver Quantitative
Tejara Capital Ltd Buys New Stake in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron (HRTX) Results Review: EPS Comes in Below Forecast on the Day; Price Reaction: Shares Move 4.13% Down in Latest TradingEarnings Turnaround - vinanet.vn
Heron Therapeutics Earnings Call: Growth Meets New Risks - TipRanks
Heron (HRTX) Watch: Records a 4.65% Increase to $0.31 at the Close; Key Range: the Session Ends Within the Reported Technical Boundaries in the Available RecordIV Contraction - vinanet.vn
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Hold Rating - Moomoo
Weekly Recap: Guidance withdrawn over CINVANTI patent and HRTX Q2 revenue $37.7M - TradingView
HC Wainwright Has Pessimistic Outlook of HRTX Q3 Earnings - MarketBeat
HERON THERAPEUTICS INC : H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY - webull.com
H.C. Wainwright Downgrades Heron Therapeutics(HRTX.US) to Hold Rating - Moomoo
Heron Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com Canada
Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ... - finance.yahoo.com
Heron Therapeutics Q2 2026 Loss Widens 50.0% Beyond Estimates - AlphaStreet
Heron Therapeutics: Q2 Earnings Snapshot - AOL.com
Heron Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Heron Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook - Yahoo Finance
Earnings call transcript: Heron Therapeutics misses Q2 2026 revenue forecast By Investing.com - Investing.com Canada
Heron Therapeutics Q2 Earnings Call Highlights - MarketBeat
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
development in the article - Minichart
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results - MarketBeat
HERON THERAPEUTICS INC HERON TH (0J4V.L) Q2 FY2026 earnings call transcript - Yahoo Finance
Heron Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Heron Therapeutics Q2 revenue rises on acute care growth, withdraws 2026 outlook - TradingView
Heron Therapeutics Q2 Revenue Rises To $37.7 Million - Quiver Quantitative
Heron Therapeutics reports Q2 2026 revenue $37.7M, withdraws 2026 guidance after patent ruling - TradingView
Wall Street Zen Upgrades Heron Therapeutics (NASDAQ:HRTX) to Sell - MarketBeat
HERON THERAPEUTICS Q2 2026 Earnings Preview: Recent $HRTX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Heron Therapeutics Inc expected to post earnings of 1 cent a shareEarnings Preview - TradingView
HRTX Q1 2026 Earnings: EPS Misses Estimates as Net Loss WidensEarnings Miss Streak - vinanet.vn
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Heron Therapeutics (NASDAQ:HRTX) Upgraded to Hold at Zacks Research - MarketBeat
Earnings Preview: HRTX to Report Financial Results Pre-market on August 10 - Moomoo
HRTX Q2'26 Earnings: revenue estimate is 42.19M USD - TradingView
Heron Therapeutics (HRTX) Projected to Post Quarterly Earnings on Monday - MarketBeat
Heron Therapeutics, Inc. Revenue Breakdown – NASDAQ:HRTX - tradingview.com
HRTX Q1 2026 Earnings: Wider-than-Expected Loss Signals Ongoing Cost PressureEPS Estimate Trend - vinanet.vn
Heron Therapeutics Inc Revenue Breakdown – BX:AXD2 - TradingView
Heron Therapeutics Inc (HRTX) Institutional Confidence - TradingKey
Heron Therapeutics to Report Second Quarter 2026 Financial Results on August 10 - Quiver Quantitative
Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026 - The Manila Times
Orbimed Advisors LLC Makes New Investment in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron Therapeutics Inc (HRTX) Cash Flow - TradingKey
Heron Therapeutics Inc (HRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Heron Therapeutics Inc (AXD2) Q4 2022 Earnings ReportResults, Call & Slides - TipRanks
Heron Therapeutics Inc Stock (HRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):